Intermittent capecitabine to reduce clonal evolution in patients with luminal B, HR-positive HER2- negative metastatic breast cancer treated with CDK4/6 inhibitors and aromatase-inhibitors.

All Patients receive CDK4/6 inhibitors and aromatase inhibitor (AI). After 6 months of therapy Patients will be randomized 2:1 to the following arms: a) Experimental arm: alternating between capecitabine (7 days therapy followed by 7 days break) for 3 months and ribociclib+ aromatase inhibitor (AI) for 3 months. (In total for 1,5 years after randomization or until progressive disease, whichever occurs first). b) Standard Arm: continuous CDK 4/6 inhibitors and AI

Status: In Vorbereitung

Klinische Settings

Beteiligte

Identifier

Kontakt